BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022)

BridgeBio Pharma (BBIO) reported Asset Writedowns and Impairment of $67000.0 for Q3 2022, down 99.47% sequentially from $12.7 million in Q1 2022.

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022) Analysis & Trends

BridgeBio Pharma (BBIO) has 2 years of Asset Writedowns and Impairment data on file, last reported at $67000.0 in Q3 2022.

For the quarter ending Q3 2022, Asset Writedowns and Impairment changed N/A year-over-year to $67000.0; the trailing twelve-month figure through Jun 2023 stood at $67000.0 (down 99.28% YoY), and the FY2024 full-year result was $271000.0, changed N/A from the prior year.
Asset Writedowns and Impairment declined to $67000.0 in Q3 2022, from $12.7 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $12.7 million in Q1 2022 to a low of -$3.3 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	BridgeBio Pharma	16.15 Bn	15.22 Bn	184.58 Mn

Download Data